Phase III study of intermittent 5‐drug regimen (VBCMP) versus intermittent 3‐drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis
- 1 November 1985
- journal article
- clinical trial
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 35 (5), 518-524
- https://doi.org/10.1111/j.1600-0609.1985.tb02822.x
Abstract
A prospective randomized trial in 96 patients with previously untreated myelomatosis was performed comparing 3 regimens of chemotherapy: (i) Intermittent vincristine, BCNU, cyclophosphamide, melphalan, and prednisone (VBCMP) to (ii) intermittent vincristine, melphalan and prednisone (VMP) to (iii) intermittent melphalan and prednisone (MP). Induction response rates and survival were similar in all 3 regimens. An improvement in relapse-free survival was observed by adding vincristine to MP, but this did not achieve statistical difference (p = 0.10). Patients given VBCMP fared slightly worse than those given VMP. The haematologic toxicity was similar in all 3 regimens, but the tolerability of VBCMP was lower. Although showing no statistical differences between the 3 treatment regimens, the results support the view that a combination of MP 'standard' induction therapy in MM with frequently administered vincristine has a trend towards postponing treatment failure due to development of resistance to melphalan.Keywords
This publication has 14 references indexed in Scilit:
- Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myelomaBlood, 1984
- Treatment of multiple myeloma with M-2 protocol and without maintenance therapyEuropean Journal of Cancer and Clinical Oncology, 1983
- Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experienceCancer, 1982
- Treatment comparisons in the third MRC myelomatosis trial.British Journal of Cancer, 1980
- Report on the second myelomatosis trial after five years of follow-up.British Journal of Cancer, 1980
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979
- Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGBBlood, 1979
- Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocolAmerican Journal Of Medicine, 1977
- Combination therapy for multiple myelomaCancer, 1977
- Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNUCancer, 1974